T cell therapy leading to prolonged remission for children with aggressive leukaemia

Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma

ASH 2014: Expert discussion on the latest in AML

ASH 2014: Expert discussion on the latest in CLL

Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive multiple myeloma

Investigational antibody demonstrates efficacy, safety for patients with aggressive multiple myeloma in phase I study

HIV-associated lymphoma responds well to stem cell transplantation

Daratumumab plus standard treatment improves outcomes in relapsed, hard-to-treat multiple myeloma in phase I study

Stem cell transplantation safe for patients with HIV-associated lymphoma

Carfilzomib represents potent, effective addition to standard multiple myeloma therapy in phase III study

Brentuximab vedotin prolongs post-transplant survival in hard-to-treat lymphoma patients in phase III study

Children with aggressive leukaemia experiencing remission with T cell therapy